Dyadic International (DYAI) vs Estrella Immunopharma (ESLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dyadic International (DYAI) has outperformed Estrella Immunopharma (ESLA) over the past year, losing 60.7% versus a loss of 67.9%. Over five years, DYAI leads with a -90.8% price change compared with -95.8% for ESLA. Estrella Immunopharma is the larger company by market cap ($17.8 million vs $17.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | ESLA |
|---|---|---|
| Share price | $0.444 | $0.41 |
| Market cap | $17.79M | $17.83M |
| 1-day change | -0.09% | -1.80% |
| YTD return | -52.72% | -73.24% |
| 1-year return | -60.67% | -67.88% |
| 5-year return | -90.84% | -95.77% |
| EPS (TTM) | $-0.23 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $3.15 |
| 52-week low | $0.34 | $0.3083 |
| Distance from 52-week high | -72.25% | -86.98% |
| Analyst consensus | none | none |
| Avg. price target upside | +1138.74% | +2826.83% |
| Average volume | 201.91K | 38.61K |
| Shares outstanding | 40.06M | 43.50M |
| Employees | 5 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
DYAI vs ESLA FAQ
Which is bigger, Dyadic International or Estrella Immunopharma?
Estrella Immunopharma (ESLA) is larger, with a market capitalization of $17.83M compared with $17.79M for Dyadic International (DYAI).
Which stock has performed better over the past year, DYAI or ESLA?
DYAI returned -60.67% over the past 12 months, compared with -67.88% for ESLA (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and Estrella Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.